{"name":"Alkermes, Inc.","slug":"alkermes-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":500000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Aristada","genericName":"ARIPIPRAZOLE LAUROXIL","slug":"aripiprazole-lauroxil","revenue":500000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2015-01-01","label":"Aristada first approved","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Lybalvi first approved","drug":"Lybalvi","drugSlug":"samidorphan","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2032-11-07","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-09-19","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-24","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-24","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2033-10-24","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Method of Use)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"},{"date":"2035-03-19","label":"Aristada patent expiry (Formulation)","drug":"Aristada","drugSlug":"aripiprazole-lauroxil","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":500000000,"percentOfTotal":100,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Aristada","genericName":"ARIPIPRAZOLE LAUROXIL","slug":"aripiprazole-lauroxil","indication":"Schizophrenia","status":"marketed","revenue":500000000},{"name":"OLZ/SAM","genericName":"OLZ/SAM","slug":"olz-sam","indication":"Treatment of schizophrenia","status":"phase_3"},{"name":"ALK3831","genericName":"ALK3831","slug":"alk3831","indication":"Schizophrenia (maintenance treatment)","status":"phase_3"},{"name":"ALKS 2680 Dose 1","genericName":"ALKS 2680 Dose 1","slug":"alks-2680-dose-1","indication":"Cognitive impairment associated with schizophrenia","status":"phase_3"},{"name":"ALKS 37","genericName":"ALKS 37","slug":"alks-37","indication":"Treatment-resistant schizophrenia","status":"phase_2"},{"name":"Baclofen ER","genericName":"Baclofen ER","slug":"baclofen-er","indication":"Spasticity associated with multiple sclerosis","status":"marketed"},{"name":"High Dose ALKS 5461","genericName":"High Dose ALKS 5461","slug":"high-dose-alks-5461","indication":"Major depressive disorder (Phase 3)","status":"phase_3"},{"name":"LYBALVI","genericName":"LYBALVI","slug":"lybalvi","indication":"Schizophrenia","status":"marketed"},{"name":"Lybalvi","genericName":"SAMIDORPHAN","slug":"samidorphan","indication":"Schizophrenia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"ALKS 33","genericName":"ALKS 33","slug":"alks-33","indication":"Other","status":"phase_1"},{"name":"ALKS 33-BUP","genericName":"ALKS 33-BUP","slug":"alks-33-bup","indication":"Other","status":"phase_1"},{"name":"ALKS 3831","genericName":"ALKS 3831","slug":"alks-3831","indication":"Other","status":"phase_3"},{"name":"ALKS 9072, Med dose","genericName":"ALKS 9072, Med dose","slug":"alks-9072-med-dose","indication":"Other","status":"phase_1"},{"name":"Motrin","genericName":"Motrin","slug":"motrin","indication":"Other","status":"marketed"},{"name":"NTX/PBO-B","genericName":"NTX/PBO-B","slug":"ntx-pbo-b","indication":"Chronic weight management in obese or overweight adults with weight-related comorbidities","status":"phase_3"},{"name":"VIVITROL 380mg","genericName":"VIVITROL 380mg","slug":"vivitrol-380mg","indication":"Other","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"ALKS 9072","genericName":"ALKS 9072","slug":"alks-9072","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"ALKS 9072, High","genericName":"ALKS 9072, High","slug":"alks-9072-high","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"ALKS 9072, Low","genericName":"ALKS 9072, Low","slug":"alks-9072-low","indication":"Opioid use disorder","status":"phase_3"},{"name":"Low Dose ALKS 5461","genericName":"Low Dose ALKS 5461","slug":"low-dose-alks-5461","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"NTX/BUP","genericName":"NTX/BUP","slug":"ntx-bup","indication":"Opioid use disorder (maintenance treatment)","status":"phase_3"},{"name":"PBO-N/PBO-B","genericName":"PBO-N/PBO-B","slug":"pbo-n-pbo-b","indication":"Moderate to severe pain","status":"phase_3"}]}],"pipeline":[{"name":"Aristada","genericName":"ARIPIPRAZOLE LAUROXIL","slug":"aripiprazole-lauroxil","phase":"marketed","mechanism":"Aristada works by blocking dopamine receptors in the brain to help regulate abnormal thought and behavior patterns.","indications":["Schizophrenia"],"catalyst":""},{"name":"OLZ/SAM","genericName":"OLZ/SAM","slug":"olz-sam","phase":"phase_3","mechanism":"OLZ/SAM is an oral, fixed-dose combination of olanzapine and samidorphan, a partial agonist at the μ-opioid receptor.","indications":["Treatment of schizophrenia"],"catalyst":""},{"name":"ALK3831","genericName":"ALK3831","slug":"alk3831","phase":"phase_3","mechanism":"ALK3831 is a long-acting injectable formulation of aripiprazole designed to provide sustained dopamine D2/D3 receptor antagonism for antipsychotic effect.","indications":["Schizophrenia (maintenance treatment)","Bipolar I disorder (maintenance treatment)"],"catalyst":""},{"name":"ALKS 2680 Dose 1","genericName":"ALKS 2680 Dose 1","slug":"alks-2680-dose-1","phase":"phase_3","mechanism":"ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms.","indications":["Cognitive impairment associated with schizophrenia","Negative symptoms of schizophrenia"],"catalyst":""},{"name":"ALKS 33","genericName":"ALKS 33","slug":"alks-33","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALKS 33-BUP","genericName":"ALKS 33-BUP","slug":"alks-33-bup","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALKS 37","genericName":"ALKS 37","slug":"alks-37","phase":"phase_2","mechanism":"ALKS 37 is a dual GABA_A receptor agonist.","indications":["Treatment-resistant schizophrenia"],"catalyst":""},{"name":"ALKS 3831","genericName":"ALKS 3831","slug":"alks-3831","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALKS 9072","genericName":"ALKS 9072","slug":"alks-9072","phase":"phase_3","mechanism":"ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"ALKS 9072, High","genericName":"ALKS 9072, High","slug":"alks-9072-high","phase":"phase_3","mechanism":"ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"ALKS 9072, Low","genericName":"ALKS 9072, Low","slug":"alks-9072-low","phase":"phase_3","mechanism":"ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms.","indications":["Opioid use disorder"],"catalyst":""},{"name":"ALKS 9072, Med dose","genericName":"ALKS 9072, Med dose","slug":"alks-9072-med-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Baclofen ER","genericName":"Baclofen ER","slug":"baclofen-er","phase":"marketed","mechanism":"Baclofen ER is a GABA-B receptor agonist that reduces neuronal excitability and muscle tone by enhancing inhibitory neurotransmission in the central nervous system.","indications":["Spasticity associated with multiple sclerosis","Spasticity resulting from spinal cord injury or disease","Muscle spasticity of other origins"],"catalyst":""},{"name":"High Dose ALKS 5461","genericName":"High Dose ALKS 5461","slug":"high-dose-alks-5461","phase":"phase_3","mechanism":"ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through antagonism at the opioid receptor.","indications":["Major depressive disorder (Phase 3)","Opioid use disorder (earlier development stage)"],"catalyst":""},{"name":"LYBALVI","genericName":"LYBALVI","slug":"lybalvi","phase":"marketed","mechanism":"LYBALVI is a combination of lurasidone (an atypical antipsychotic) and samidorphan (an opioid antagonist) that blocks dopamine and serotonin receptors while antagonizing opioid receptors to reduce antipsychotic-induced weight gain.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)"],"catalyst":""},{"name":"Low Dose ALKS 5461","genericName":"Low Dose ALKS 5461","slug":"low-dose-alks-5461","phase":"phase_3","mechanism":"ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through opioid antagonism.","indications":["Moderate to severe acute pain","Chronic pain management"],"catalyst":""},{"name":"Lybalvi","genericName":"SAMIDORPHAN","slug":"samidorphan","phase":"marketed","mechanism":"Lybalvi blocks the action of opioids at their receptor sites in the brain.","indications":["Schizophrenia","Bipolar I Disorder - Acute Manic or Mixed Episodes","Bipolar I Disorder - Maintenance Monotherapy"],"catalyst":""},{"name":"Motrin","genericName":"Motrin","slug":"motrin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NTX/BUP","genericName":"NTX/BUP","slug":"ntx-bup","phase":"phase_3","mechanism":"NTX/BUP is a fixed-dose combination of naltrexone (an opioid antagonist) and buprenorphine (a partial opioid agonist) that reduces opioid cravings and withdrawal symptoms while blocking euphoric effects of additional opioid use.","indications":["Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"NTX/PBO-B","genericName":"NTX/PBO-B","slug":"ntx-pbo-b","phase":"phase_3","mechanism":"NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss.","indications":["Chronic weight management in obese or overweight adults with weight-related comorbidities"],"catalyst":""},{"name":"PBO-N/PBO-B","genericName":"PBO-N/PBO-B","slug":"pbo-n-pbo-b","phase":"phase_3","mechanism":"PBO-N/PBO-B is a partial opioid agonist.","indications":["Moderate to severe pain"],"catalyst":""},{"name":"VIVITROL 380mg","genericName":"VIVITROL 380mg","slug":"vivitrol-380mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZzBpX2NhNDNMSXFoWHlDREUtZ2k3NmstVnZ2ZVlPZVg4dFlIbEZzWFdZRUZDbDZQWTRnaUlNeEQ3d1F5ZENOUXBmRkNZMHQzUWc4MjZ1ekVGbmtEMDJtSWxwX3pRcVplb1VkOU9fS3F3RkNlc1ZnSk9ZSDRzMHM5NmJlZjlwYV9odDNUUkJFWG5LcHYwaC1xbGd2OA?oc=5","date":"2026-03-06","type":"pipeline","source":"Pharma Voice","summary":"Biopharma’s recent string of CEO splits - Pharma Voice","headline":"Biopharma’s recent string of CEO splits","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQXzg2amZWSU5selR3ajl0MVZyS1ZKbVYtNGI0ekpQOHdYMnV6S1VGTHUtc0tqWmR2MUNRUkJwNlp4dzRxTFR4Y1ZTc2xwVmhNVjJVNlNRZWd2Y3R3NVVncFdmY3doVXhCcEw1NGtWOXZkS1d6ODVXMDZLVy1Pb21HRVB3b2xoTndGd0E?oc=5","date":"2026-02-26","type":"pipeline","source":"The Pharma Letter","summary":"Alkermes announces CEO succession plan - The Pharma Letter","headline":"Alkermes announces CEO succession plan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVEFUdFpFYkdEaHZ1eDVWWUxQbFlSTk1zRDZWQTBhR3pfUUlNQXB1SWMydjBlSWZ1U1prRFU2ZXlXdllMd3RHX0pWaUdqMjRFN05HS3h0LWlOLWdTa2o5T2NPaEc4Z0lGRERFNDZOQ0l4Rkphb2NLLTB6WWV5YVYzZk1Ma2VKbWNqajVMbmZ5X3o3THRFa3VNX2NGRVlsNEJhT2hHTVgxNE1sdw?oc=5","date":"2026-02-13","type":"regulatory","source":"CHEManager","summary":"Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals - CHEManager","headline":"Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxONzVLam5yelRDaGxiYWJERlRVeDFKR3FMN3lDVjkzYmE5SV9OWGpTRndtREJnZUFjWEdlaF8tbEJVQmJlSHNYSXRWS0dBX2dSYmxVdmxsQ2h1eVZkS296bGp0cmxTc2tfdEM0MkdkQTZEWDcya29TSE53OHdmc2tqWG9weDBCVTR2MHN3T3VfdHA?oc=5","date":"2026-02-12","type":"pipeline","source":"Yahoo Finance","summary":"Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - Yahoo Finance","headline":"Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxPaUVueWtFeDVsSHBUcVFpdFRPZlluYlEzTkNxc3ZVZElXdktuaC16anZpOU1mc09pOGFsQnVKNXItY3Z0SkZLbmNjUVctdVNUVGhtX3hZRmZ3Ujc0bW9Md1RhaHBRczFZZFdSRnIySng4TVk5eDRXbDJnUUE4YmVvSUFyV3Y3SXFmZjZ5cFV2Tk56amYxNWFhRFFjaTc0X2N3NFVlSXpSbE5LdFdSenUxaUJGSGk1Y2dmY3l5TW95UG9VQjVteW1FTTA0WGtZNGJ6bEFoTWxIZTR4VmFmb1JZ?oc=5","date":"2026-02-10","type":"regulatory","source":"Quiver Quantitative","summary":"Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc - Quiver Quantitative","headline":"Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOTFdjaXZZYUFMZzNDTjBqcENrS180bzgyZEszNE5HdmRwV3lqWFd2REtkUXhGcFc3clVnaEtLMkszc2k0eE1talVwTk9LVmF3NnFVZ3ZfUm9ELTA5NkVrQy1BWGFURWc5bXVCM3V0NjVlSVBZZ29YSEVJcnRhVG4tMlBLZGY1NGdJZWVVSGVaaTB1TDh4NkZXb2FRN3JHS0N1WmN3Qi1HcWVPVVhBeHFsdXlvVUFkVjdzX05ST3BrM3VSYmtSLVE?oc=5","date":"2025-12-01","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer - Genetic Engineering and Biotechnology News","headline":"Lundbeck Ends Bidding War for Avadel, After Alkermes’ Up-to-$2.37B Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQLS1rQS1ZLWRHZEE1WWdBTEpWdWlUWDF4MTA5ZzVqZ09SV01hdnZ1OEZWV0xiSEVSLTY2eWU0MjBfdzJNOVRWVWpXamFHUzYzTkNpYm5HamM5SnJNYkZ3Szdmby01UWZVek12TFg0X04xM2ZXcDhkc3NidnpnbWFqUnplM3JiVGRMbzVZV0tDbG5ySm9Qa1E2VldNc08wMzVVNkJwUnVHek1ydEcwVS0tejc2bWkwQlRKb3p3eEZRc2VRX0dBcXRtZEhJRTA?oc=5","date":"2025-11-19","type":"deal","source":"prnewswire.com","summary":"Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc - prnewswire.com","headline":"Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPR2dlanlIdjZnQ25sTkYzN1Bkd0JWNUZNSTVINERNMnZ0a293b2psQWVCeTJfZHdpSDBieURtdmRiWWZIdUtGc01ISHdmcElZNVJEMjBzZFpSNzRBREpfSDcyWVhmZ3lBM1JiNVN2UEJsd3M0bFpNU1JFLXh3ZEhZaTlUOUJzU01CMHlWS21wNHpDSHNSRzRqRzJ6U2plVTRSRmJwVkxYSGs2TFloTzBtSG01eUZMT1lvdXpXRw?oc=5","date":"2025-11-14","type":"pipeline","source":"BioPharma Dive","summary":"To Wall Street, a new bidding war puts Alkermes in a tough spot - BioPharma Dive","headline":"To Wall Street, a new bidding war puts Alkermes in a tough spot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUmlOeEJVMjA0YWdJbWRpZHhzcHhlcjdpNm0zcURUYkRIUEpqMVFPb05zLVdQTGVKYW96REpickxnQzhhM3h6dXQ0cWV5MmwxbEFxM1BiUHZFRVd1MkJBQ3oxUlNDLWJsMF93YmxXdTdjbll0aktSNmw1QzRDQ1lNbXJHOWRTa0Zpd2lKdGxEb1hxR0hMZWtRNkphWEFldFNLUHNiUEVrcWFoTDhDTVJxRnBIWjVLemVveEVV?oc=5","date":"2025-11-05","type":"pipeline","source":"The Business Journals","summary":"Drug company's St. Louis-area operations to be 'under review' in $2.1B planned sale - The Business Journals","headline":"Drug company's St. Louis-area operations to be 'under review' in $2.1B planned sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNZERzNmh2U0g5b3kyWGJlWE5KdFVwOWRaLURTNG1zS0xyYXlUR1dUa2R1Qk5kRHAxbmdheldZX0pxTFB0SXQzR1F5RFYxS2dkTlpCZlVaN1pjSVc4VlE1UC1GVjgwWnMxclM3NHItY1VpbUhqUzg2VmsyaXhlWlRoeHYyUDNqdWZLNFFITXoxaWpjRmIyME9BbmpuekU0aDRBV0ZHNTdUdw?oc=5","date":"2025-10-22","type":"deal","source":"Contract Pharma","summary":"Alkermes to Acquire Avadel Pharmaceuticals for $2.1 Billion - Contract Pharma","headline":"Alkermes to Acquire Avadel Pharmaceuticals for $2.1 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQdFZ4U2VMS0w2MGVVUjZ4WDdsRklQM1N0UUw1QmlhanZacUx6bG91T3Nid3hsbkp2OWpJX3Y5cE9WdlcxZWNoUmNiQjZtMnRUVDhZQTFudVNpX09aZmZiQlJnWFdjSzlfNHNYSjdzZEQ1SW5SUnNCRVhHR3lJdTkxVmJXRXVWdk14MmxYS2VwbUJ3M3VOYWQ2TFA3WHVaeFNTemdlUDV1cG82RzBaQU9RQg?oc=5","date":"2025-10-22","type":"pipeline","source":"Fierce Pharma","summary":"Alkermes plots $2.1B acquisition of Avadel and its long-acting narcolepsy drug Lumryz - Fierce Pharma","headline":"Alkermes plots $2.1B acquisition of Avadel and its long-acting narcolepsy drug Lumryz","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQMEgxZmpRRU04QmdDOHRnaHBsNjNlSnpRNHJvcUtkUW9nYjRUMTV4LWstTnhNeF9adjJxQ1A3LVB4Umwtb3phY0Z1SW4zNWFuX3lHS0l4Q25zc1FPSXhyUmxYczlfV05EbzRVZi1MS0VyOVN3eExnSDdSRE4yUTFVRGpSejlQTWtuVTFWTkZkS0Vld0s3VklwenhhZm52VmlSOTd0RmE0NGl4YmVXcVE?oc=5","date":"2025-10-03","type":"patent","source":"Reuters","summary":"Alkermes sued over alleged scheme to block generic Vivitrol - Reuters","headline":"Alkermes sued over alleged scheme to block generic Vivitrol","sentiment":"neutral"}],"patents":[{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"10226458","type":"Method of Use","expiryDate":"2032-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9034867","type":"Formulation","expiryDate":"2032-11-07","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"12311027","type":"Formulation","expiryDate":"2033-09-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9193685","type":"Formulation","expiryDate":"2033-10-24","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"11097006","type":"Formulation","expiryDate":"2033-10-24","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"11969469","type":"Formulation","expiryDate":"2033-10-24","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9452131","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"10238651","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"10813928","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"11406632","type":"Method of Use","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]},{"drugName":"Aristada","drugSlug":"aripiprazole-lauroxil","patentNumber":"9526726","type":"Formulation","expiryDate":"2035-03-19","territory":"US","annualRevenue":500000000,"genericFilings":[]}],"drugCount":22,"phaseCounts":{"marketed":6,"phase_3":12,"phase_1":3,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}